Psilocybin administration to healthy participants: safety and feasibility in a placebo-controlled study

Abstract

Adverse events • 511 AEs were reported throughout the 12-week duration of the study: 217 in the 25mg psilocybin arm (reported by 96.7% of participants); 203 in the 10mg psilocybin arm (reported by 96.7% of participants); and 91 in the placebo arm (reported by 89.7% of …